PTEN公司
蛋白激酶B
癌症研究
细胞凋亡
活力测定
细胞生长
厌氧糖酵解
肺癌
化学
癌症
癌细胞
生物
药理学
PI3K/AKT/mTOR通路
医学
病理
内科学
生物化学
作者
Xiufeng Jiang,Wei Zhao,Feng Zhu,Hui Wu,Xiao-Ping Ding,Jinmei Bai,Xiaoqing Zhang,Meifang Qian
标识
DOI:10.1016/j.taap.2020.115336
摘要
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related death worldwide. The abnormal activation of glycolytic metabolism and PTEN/AKT signaling in NSCLC cells are highly correlated with their proliferation abilities and viability. Ligustilide is one of the major bioactive components of multiple Chinese traditional medicine including Angelica sinensis and Ligusticum. Ligustilide exposure inhibits the proliferation and viability of multiple cancer cell lines in vitro. However, the impact of ligustilide to the progression of NSCLC and its detailed pharmacological mechanisms remain unclear. In this research, CCK-8 and colony formation assay were performed to demonstrate ligustilide treatment inhibited the viability and proliferation ability of NSCLC cells in vitro. Caspase-3/−7 activity assay and nucleosome ELISA assay were utilized to show ligustilide promoted the apoptosis of NSCLC cells. Metabolic analysis and qRT-PCR assay were used to demonstrated that ligustilide dampened aerobic glycolysis of NSCLC cells. Nude mice were exposed to 5 mg/kg ligustilide and ligustilide inhibited orthotopic NSCLC growth in vivo. qRT-PCR and Western blot analysis were performed to substantiate the regulatory function of ligustilide to PTEN/AKT signaling in NSCLC cells. Overall, this study revealed that ligustilide regulated the proliferation, apoptosis and aerobic glycolysis of NSCLC cells through PTEN/AKT signaling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI